Public Anchor Enterprises: Yardstick Competition and Essential Markets

Public draft prepared by Lisa / Hermes, 2026-06-14. Suggested Pond location: Government Operations and Fiscal Policy → Economic Governance and Public-Service Mandates. This is public-facing analysis, not legal advice, investment advice, industrial-policy instruction, or a certification claim.

Summary

The question is not "private bad, public good." That frame is too blunt for the problem.

The better question is strategic: which industries or services are too important to leave entirely to private market signals, and where should a public or nonprofit anchor be placed to discipline the market without replacing it?

Healthcare and education sit close to the obvious end of that spectrum because society has too much to lose when access, quality, and continuity are governed mainly by ability to pay or investor return. Steel is harder. Pharmaceuticals are harder still, because patented drug discovery and commodity generic production are very different markets. Postal service, elder care, energy, telecommunications, water, rail, and food security each raise their own version of the same question.

A useful public option does not have to own the whole market. Sometimes a public or mission-locked producer with only a minority share can set a reference price, reveal real costs, preserve strategic capacity, and keep private operators honest. The point is not domination. The point is a working benchmark.

The one-fifth idea

A public anchor enterprise is a minority public or mission-locked producer inside a mostly private market.

The idea is simple:

• four-fifths of the market may remain private;
• one-fifth may be public, nonprofit, cooperative, Crown-owned, or otherwise mission-locked;
• the public node sells at cost or against a clear public mandate;
• its books, pricing logic, service standard, and capacity become visible; and
• private firms must now explain their prices and service quality against a live counterexample.

That one-fifth does not have to beat the whole market. It has to reveal enough information to make market power harder to hide.

This is related to yardstick competition: the regulator, public, or purchaser gains a benchmark from a comparable producer. When concentrated private firms say a price is unavoidable, the public anchor can show whether that is true.

Why this matters

Markets often work well when there are many producers, low switching costs, clear prices, informed buyers, and no catastrophic social consequence if a firm fails. Essential services are different.

In essential markets, failure can mean:

• people lose health care, medicine, education, water, heat, mail access, transport, or emergency services;
• strategic domestic capacity disappears;
• private firms gain pricing power because the buyer cannot walk away;
• public authorities are forced to rescue the system after private extraction or underinvestment;
• workers and communities carry costs that do not appear on corporate ledgers; and
• the public cannot tell whether high prices reflect real costs or market power.

A public anchor can help where the problem is not lack of entrepreneurship, but lack of a trustworthy benchmark.

Healthcare and education: close to the public core

Healthcare and education are not ordinary consumer markets.

Healthcare fails as a pure private market because illness is unpredictable, information is asymmetric, and the people who need care most are often least able to pay. A market that sorts by profitability will tend to underserve the sick, poor, rural, elderly, disabled, and complicated. That is not a side effect; it is a predictable result of the objective function.

Education fails similarly when treated only as a private purchase. The benefits of education spill beyond the individual student into workforce capacity, democratic competence, civic trust, public health, crime reduction, innovation, and intergenerational mobility. If access depends too heavily on private purchasing power, the whole society inherits the long-term cost.

That does not mean every clinic, school, contractor, or delivery layer must be directly government-run. It means the public-interest layer must be strong enough that access, continuity, quality, and accountability are not subordinated to return on capital.

Steel: a harder strategic case

Steel is not the same as healthcare. A steel producer does not directly treat a patient or educate a child. It can fail without the same immediate human consequence.

But steel can still be strategic.

In a province or region with mines, production capacity, industrial labour, rail access, energy infrastructure, or downstream manufacturers, steel may sit inside a broader economic-resilience system. A public anchor steel producer could, in theory, serve several functions:

• preserve domestic production capacity;
• provide a cost benchmark for private producers;
• stabilize supply for downstream manufacturers during shocks;
• prevent a regional industrial base from collapsing too quickly in a downturn;
• support workforce continuity and apprenticeship capacity;
• provide emergency or defence-related capacity if needed; and
• reveal whether private pricing reflects real cost or concentrated market power.

But this is not automatically justified. Steel also carries serious risks:

• high capital cost;
• commodity price volatility;
• trade exposure;
• energy and environmental constraints;
• risk of political subsidy to a declining sector;
• pressure to protect jobs even when the market has structurally changed; and
• capture by local interests that treat public ownership as permanent insulation from reality.

The strategic question is therefore not "should steel be public?" It is:

Is there a specific layer of the steel supply chain where a public anchor would produce more resilience, transparency, or market discipline than it costs?

That answer may be yes in some places and no in others.

Strategic public ownership is not nostalgia

A public anchor is not a promise to freeze an old economy in place. It should not exist to deny change.

It is justified only where the public can state the function clearly:

• price benchmark;
• strategic reserve capacity;
• domestic supply assurance;
• workforce stabilization during cyclical shocks;
• emergency production capability;
• market discipline;
• access guarantee;
• shortage prevention; or
• public-interest research and manufacturing.

If the function cannot be named, measured, and periodically reviewed, the public anchor becomes a subsidy looking for a theory.

Pharmaceuticals: the cleanest anchor case

Pharmaceuticals show why the layer matters.

Novel patented drug discovery is uncertain, research-heavy, and innovation-driven. A public producer can contribute to research, but replacing the whole innovation system is a much bigger question.

Off-patent essential medicines are different. Many generics, sterile injectables, vaccines, and basic medicines are not mainly innovation problems. They are production, supply, pricing, shortage, and market-concentration problems.

That is where a public or nonprofit anchor can be powerful.

The anchor does not need to invent a new molecule. It needs to:

• manufacture or procure a known essential medicine;
• price it transparently;
• maintain reliable supply;
• prevent shortage-driven price spikes;
• reduce dependence on thin private supply chains;
• reveal real production and distribution costs; and
• force private sellers to compete against a credible low-cost benchmark.

In health care, this may be one of the most practical places to put a public production node.

Connaught Laboratories: Canada already built part of this model

Canada has historical experience with this idea.

Connaught Laboratories began in 1914 at the University of Toronto as a public-health-oriented laboratory. After the discovery of insulin at the University of Toronto, Connaught played a major role in producing and distributing insulin under a non-commercial public-health mandate. It also became important in vaccines and biological products.

The lesson from Connaught is not that public production is easy or permanently safe. The lesson is that Canada once had a public-interest biomedical production capacity that could support access, research, and supply.

The warning is what happened later. As Connaught's mandate and ownership structure shifted, the public-health function weakened. Eventually, the operation was sold into the private pharmaceutical sector and what remains is part of Sanofi. Canada retained expertise and industrial presence, but it lost a public-interest anchor with a mission distinct from ordinary commercial pharmaceutical production.

The critical point is this:

The mandate was the asset. Once the mandate changed, the institution became easier to treat as just another commercial asset.

Civica Rx and CalRx: the modern version

A modern example is Civica Rx in the United States, a nonprofit drug manufacturer founded by hospital systems, philanthropies, and public-interest partners to address shortages and high prices for generic medicines. Civica focuses on essential generic drugs, including sterile injectables, where market failures can create serious hospital supply problems.

California's CalRx insulin project shows the same logic in public form. The state pursued low-cost insulin under a public label, with announced pricing around $11 per pen for insulin glargine beginning in 2026 through a Civica-arranged agreement.

That matters even before every unit is sold. A credible public or nonprofit anchor can discipline the market by threatening to reveal the price that should have existed all along.

But it also shows the recurring danger. Public manufacturing capacity requires capital, patience, and protection from budget-cycle erosion. The easiest thing to cut is often the very capacity that makes the anchor strategic.

A white-label or procurement arrangement can lower prices. Actual production capacity provides deeper insurance. Those are not the same thing.

The two ways public anchors die

Public anchors tend to fail in two ways.

1. Starvation or sale

The anchor threatens incumbent margins, so pressure builds to defund it, narrow it, outsource it, sell it, or prevent it from scaling. The public sees the cost of maintaining the anchor, while the avoided overpricing, shortages, and extraction are less visible.

The anchor can then be described as inefficient precisely because it is doing the thing it was built to do: impose a public-interest constraint on a market.

2. Mandate drift

The anchor is told to behave like a profit-maximizing competitor. It raises prices, cuts mission functions, pursues return, hides costs, imitates the private firms, and loses its reason to exist.

Once that happens, privatization becomes easier to justify. The public is no longer comparing a market to a public-interest benchmark; it is comparing private firms to a weak firm with confused objectives.

Again, the mandate is the asset.

How to decide where a public anchor belongs

A public anchor should be considered where several conditions are present:

1. Essentiality: failure affects health, safety, education, food, water, communication, emergency response, strategic industry, or basic civic functioning.
2. Market concentration: a small number of firms can shape prices, access, supply, or terms.
3. Cost opacity: buyers and regulators cannot easily tell whether prices reflect real cost or market power.
4. Commodity layer: at least part of the good or service is standardized enough for a public benchmark to be meaningful.
5. Shortage risk: underproduction or fragile supply chains create public harm.
6. Public downside: when private failure occurs, government or communities are forced to absorb the cost.
7. Measurable benchmark: price, quality, access, uptime, supply level, or service standard can be measured.
8. Mandate clarity: the public node's purpose is specific enough to audit.
9. Political insulation: the institution can resist capture, starvation, or profit-mandate drift long enough to matter.

A public anchor is weaker where the product is highly differentiated, innovation-driven, rapidly changing, or where the public sector cannot define the benchmark without freezing progress.

The public anchor test

Before creating or preserving a public enterprise in a mixed market, ask:

• What market failure is it correcting?
• Is the failure at the financing, delivery, production, infrastructure, data, or procurement layer?
• Does the public node need to dominate the market, or only set a benchmark?
• What price or service standard will it reveal?
• What private behaviour is it meant to discipline?
• What will prevent mandate drift toward profit maximization?
• What will prevent political subsidy to genuine obsolescence?
• What public harm would occur if the anchor disappeared?
• Who benefits financially if it is sold, starved, or outsourced?
• How often will the mandate be reviewed, and by whom?

If those questions cannot be answered, public ownership may be symbolic rather than strategic.

My take

The strongest version of the argument is not that government should run everything important. It is that some markets need a public-interest node placed at the point where market failure actually propagates.

For healthcare, that node is often financing and access, with delivery remaining mixed. For essential medicines, it may be production or procurement. For education, it is universal access and public standards. For steel or other strategic inputs, the case depends on geography, supply chains, industrial policy, and whether a public producer can reveal cost or preserve resilience without becoming a permanent zombie subsidy.

The public anchor is a check-and-balance mechanism. It keeps private markets from becoming completely self-referential. It gives government better information than lobbying and consultant reports. It gives citizens a live benchmark. It gives the economy a reserve capacity that ordinary market incentives may not maintain.

But it only works if the mandate is protected. A public producer ordered to maximize profit becomes a private firm in public clothing. A public producer protected from all feedback becomes a subsidy trap. The hard work is not choosing public or private once and for all. The hard work is matching the public node to the specific failure and keeping its mandate alive.

Suggested RIPPLE chain

market concentration / cost opacity → inflated price or fragile supply → public anchor enters at commodity or essential layer → reference price and supply benchmark become visible → private firms face pricing and service discipline → incumbent pressure to starve, capture, or privatize anchor → mandate protection determines whether the public benefit persists.

Key variables to track:

• essentiality of good or service;
• market concentration;
• cost opacity;
• public anchor capacity share;
• benchmark price;
• supply reliability;
• strategic domestic capacity;
• mandate clarity;
• political insulation;
• incumbent pressure;
• capture risk;
• profit-mandate drift;
• public downside if failure occurs; and
• review / correction mechanism.

Sources and starting points

This draft was prepared from public history and reporting leads that should be checked again before final publication:

• Historical material on Connaught Laboratories, insulin production, vaccine production, and later privatization into what is now Sanofi's Canadian vaccine presence.
• Public reporting and institutional material on Civica Rx as a nonprofit generic drug manufacturer focused on essential medicines and hospital shortages.
• California / CalRx public announcements and reporting on low-cost insulin glargine pricing through Civica-arranged supply.
• Economic literature on yardstick competition and public benchmarks in regulated or concentrated markets.
• Canadian public-policy debates on Crown corporations, healthcare financing, pharmaceutical access, industrial strategy, and strategic domestic capacity.

Status

Public draft for review and placement. Recommended Pond placement: Government Operations and Fiscal Policy → Economic Governance and Public-Service Mandates (taxonomy_forums_target_id = 34558).